Qinecsa has announced that it has been selected as technology partner for AfriVigilance, a new continent-wide medicines safety surveillance platform being developed by the African Medicines Agency (AMA), with implementation already underway.
The platform is intended to connect medicines, vaccines and medical device safety data across the product lifecycle, from clinical trials through to real-world use.
It will provide African National Regulatory Authorities (NRAs) with a shared system for capturing, analysing and exchanging safety information.
Under AMA governance, Qinecsa will provide consulting and technical delivery, including its HaloPV case management and QVW signal detection and management technologies.
The system will be supported by Africa-based cloud hosting.
Building on MHRA collaboration
According to Qinecsa, the project builds on its work supporting the UK’s MHRA.
The MHRA recommended Qinecsa’s technology for the project and the AfriVigilance implementation will draw on configurations used within the UK regulatory environment.
The initiative follows the African Union’s Smart Safety Surveillance (AU-3S) programme, with AMA assuming responsibility for the programme’s technical, digital and operational assets in January 2026 as part of the transition of continental medicines regulatory programmes from AUDA-NEPAD to AMA.
Strengthening pharmacovigilance across Africa
The need for greater coordination in African pharmacovigilance has also been highlighted this year by the World Health Organization (WHO).
In May, more than 300 regulators, pharmacovigilance experts and other stakeholders met in Namibia to discuss harmonising adverse-event reporting systems and practices across countries.
Qinecsa has continued to expand its pharmacovigilance technology portfolio during 2026.
In April, the company released HaloPV 6.2, adding updates covering case intake and processing, aggregate reporting, terminology management and regulatory submissions, including support for FDA E2B (R3) requirements.
Qinecsa CEO Adam Sherlock said the company’s role in AfriVigilance represents an opportunity to apply its pharmacovigilance expertise and technology to a continental-scale medicines safety programme.
"Projects [such as] this are built on trust. We’re incredibly proud that the African Medicines Agency, in collaboration with African NRAs and working alongside the MHRA, has entrusted Qinecsa with such an important role."
"This is exactly why we exist: to combine deep pharmacovigilance expertise with innovation to solve complex safety challenges that make a real difference to patients."
Helping to build a medicines safety capability at continental scale is an exciting opportunity and one we’re immensely proud to be part of.
Development of AfriVigilance has been supported by catalytic funding from the Gates Foundation.
The partners have begun implementation, with the platform intended to strengthen regulatory collaboration, generate safety evidence relevant to African populations and support more timely regulatory and public health decisions.
